Skip to content
Visit specialist site
Non-clinical specialist

Gordan Lauc, PhD

Co-Founder & Chief Scientific Officer, GlycanAge · GlycanAgeGlycobiology, glycomics, biological aging, inflammaging research

Glycobiology scientist whose IgG glycan research underpins GlycanAge's biological-age test

Portrait of Gordan Lauc, PhD

Practice

About

Gordan Lauc, PhD is GlycanAge's Co-Founder and Chief Scientific Officer and the scientist behind the IgG glycan biology the company commercializes. He is a University of Zagreb professor, founder and CEO of Genos Ltd., and co-director of the Human Glycome Project. His work connects IgG glycosylation patterns with chronic inflammation, immune aging, and biological-age estimation, giving GlycanAge its scientific foundation.

Approach

Signature approach

Lauc's role is methodology and scientific validation. His Zagreb group produced large-scale work on the plasma glycome, the human IgG glycome, and genetic drivers of glycosylation, with the 2014 Krištić et al. biological-age paper serving as a core bridge into GlycanAge's consumer test. At GlycanAge, that research becomes a practical assay for immune-aging trend tracking.

What sets them apart

  • Deep glycomics record. Google Scholar listed roughly 21,000 citations, h-index 77, and i10-index 280 at capture.
  • Genos founder. Genos developed the high-throughput IgG glycomics assay behind the product.
  • Human Glycome Project leadership. Lauc initiated the project in 2017 and serves as one of its co-directors.
  • Academic recognition. His public bios list Johns Hopkins Society of Scholars induction and visiting professorships at Johns Hopkins, University of Edinburgh, and Edith Cowan.

Training

Education

  • PhD, Biochemistry
    University of Zagreb (1995)
  • MSc, Molecular Biology
    University of Zagreb (1992)

Published work

Publications

  • Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 2014
  • Immunoglobulin G glycosylation in aging and diseases
    Cellular Immunology, 2018
  • Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological Cancers
    PLOS Genetics, 2013
  • High throughput isolation and glycosylation analysis of IgG — variability and heritability of the IgG glycome in three isolated human populations
    Molecular & Cellular Proteomics, 2011
  • Connecting genetic risk to disease end points through the human blood plasma proteome
    Nature Communications, 2017
  • Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans
    Glycobiology, 2010

Elsewhere

Media and talks

Collaboration

  • Tim D. Spector, MD
    IgG glycomics co-research; King's College London / TwinsUK; fellow GlycanAge SAB member
  • Vlatka Zoldoš, PhD
    Epigenetic regulation of glycosylation; University of Zagreb; fellow GlycanAge SAB member
  • Manfred Wuhrer, PhD
    Glycomics analytics; Leiden University Medical Center
  • Cristina Menni, PhD
    Glycan biological-age co-author (Krištić et al. 2014); King's College London
  • Jim Wilson, PhD
    Population glycomics; University of Edinburgh, Usher Institute

Verification

Profile updated

Primary sourcehttps://glycanage.com/about/our-team

Where a detail is missing, it means we have not verified it—not that the answer is no. Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.